NEWS RELEASE

Osaka Medical and Pharmaceutical University, Fukui Tateamiand Teijin Achieve Primary Endpoint in
Cardiovascular Patch Clinical Trial
Tokyo, Japan, May 17, 2022 --- Osaka Medical and Pharmaceutical University, Fukui
Tateami Co., Ltd. and Teijin Limited announced today that they have achieved theprimary efficacy endpoint in an ongoing clinical trial of the OFT-G1 (provisional name)patch for cardiovascular surgery. The trial, which began in May 2019 to examine
patients ranging from infants to adults suffering from congenital heart diseases, hasdemonstrated the safety and efficacy of the patch in one-year periods following surgery.

OFT-G1 patch in use (image)

OFT-G1 patch

The three partners now plan to apply for approval and launch the OFT-G1 patch for
cardiovascular surgery as quickly as possible in Japan and then other countries
worldwide. Simultaneously, they will continue enhancing the product’s capacity tocontribute to the quality of life of patients with cardiovascular diseases.
The patch is expected to alleviate physical, mental or financial burdens that patients andtheir families may experience in connection with corrective surgeries. It features arevolutionary design developed with Osaka Medical and Pharmaceutical University’sexpertise in cardiovascular surgery, Fukui Tateami’s pioneering warp-knitting technology
and Teijin’s advanced polymer-application technology. The patch, which consists of aknitted fabric made with biodegradable and non-biodegradable yarns, is coated with a
bio-absorbable cross-linked gelatin. Its biotechnological design is expected to enhance
the regeneration of natural tissue in patients and adaptability to growing organs inyoung patients.
Development was supported by a program launched in 2017 by the Japan Agency for
Medical Research and Development (AMED) to facilitate collaboration between medical
academia and industry. Also, in April 2018, Japan’s Ministry of Health, Labor andWelfare designated the OFT-G1 as a “SAKIGAKE” product qualifying for various
incentives to speed up approval for clinical use.

Treatments have been devised to improve the long-term survival of patients who
undergo cardiovascular surgery for purposes such as replacing defective heart tissue orenlarging narrowed blood vessels (stenosis). Demands are growing for advanced
treatments that are less likely to cause stenosis due to the patient’s somatic (physical)
growth in areas where patches have been implanted, thereby eliminating needs forfollow-up operations to replace patches that have deteriorated or calcified after
long-term implantation.
About Osaka Medical and Pharmaceutical University
Osaka Medical and Pharmaceutical University was started in 2021 by integrating theOsaka Medical College founded in 1927, and Osaka University of Pharmaceutical
Sciences founded in 1904. Osaka Medical and Pharmaceutical University has threefaculties of Medicine, Pharmaceutical Sciences, and Nursing.
URL: https://www.ompu.ac.jp/Press Contact
Section of Promoting Academia-Industry-Government Cooperation
Center for Medical Research & Development
Osaka Medical and Pharmaceutical University+81 72 684 7141
sangakukan@ompu.ac.jp
About Fukui Tateami Co., Ltd.
Fukui Tateami is a warp knitted fabric manufacturing company located in Fukui, Japan,
with 90 employees and more. Our products encompass a wide spectrum of applications,such as fashionable apparel, active sportswear, automotive interiors, industrial
materials, household textiles. With over 75 years of extensive experience and advanced
technology, Fukui Tateami has entered the medical field. It posted sales of JPY2.8billion (USD 26 million) and total assets of JPY 2.6 billion (USD 23 million) in the fiscal
year ending March 31, 2022.
Please visit http://www.fukutate.co.jp/enPress ContactGeneral Affairs
Fukui Tateami Co., Ltd.
+81 776 54 3602
info@fukutate.co.jp
About the Teijin GroupTeijin (TSE: 3401) is a technology-driven global group offering advanced solutions in thefields of environmental value; safety, security and disaster mitigation; and demographic
change and increased health consciousness. Originally established as Japan's firstrayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing
three core business domains: high-performance materials including aramid, carbon
fibers and composites, and also resin and plastic processing, films, polyester fibers andproducts converting; healthcare including pharmaceuticals and home healthcare

equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing
care and pre-symptomatic healthcare; and IT including B2B solutions for medical,
corporate and public systems as well as packaged software and B2C online services for
digital entertainment. Deeply committed to its stakeholders, as expressed in the brandstatement “Human Chemistry, Human Solutions”, Teijin aims to be a company thatsupports the society of the future. The group comprises some 170 companies andemploys some 20,000 people across 20 countries worldwide. Teijin posted consolidated
sales of JPY 926.1 billion (USD 7.2 billion) and total assets of JPY 1,207.6 billion (USD9.4 billion) in the fiscal year that ended on March 31, 2022
Press Contact
Corporate Communications
Teijin Limited
pr@teijin.co.jp